Open AccessAcute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
Author(s) -
Ishani Landry,
Nancy Hall,
Jagadeesh Alur,
Gleb Filippov,
Larisa Reyderman,
Beatrice Setnik,
Jack E. Henningfield,
Margaret Moline
Publication year - 2022
Publication title -
journal of clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001562
Subject(s) - sedative , zolpidem , placebo , medicine , zopiclone , anesthesia , crossover study , pharmacology , hypnotic , insomnia , alternative medicine , pathology
As part of a human abuse potential (HAP) study of lemborexant (LEM), the effects of therapeutic (LEM 10 mg), and supratherapeutic doses of LEM 20 mg and LEM 30 mg on cognition and psychomotor performance were compared with placebo (PBO) and supratherapeutic doses of zolpidem (ZOL) 30 mg and suvorexant (SUV) 40 mg. Subjects (n = 32) were healthy, nondependent, recreational sedative users able to discriminate the effects of both SUV and ZOL from PBO on subjective drug measures.